Beigene Stock

Beigene Goodwill

Delisted·Jun 18, 2026

Goodwill of Beigene (6160.HK) as of Aug 24, 2026.

Goodwill

0.00USD

Last updated:

Goodwill of Beigene is 2026 0.00 USD. Goodwill of Beigene was 2025 0.00 USD. It decreases by % lower compared to the previous year.

The Beigene Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2017
854,153.04 USD
Jan 1, 2018
854,153.04 USD
Jan 1, 2019
854,153.04 USD
Jan 1, 2020
125,966.71 USD
Jan 1, 2021
854,153.04 USD
Jan 1, 2022
5.94 M USD
The Beigene Goodwill history
YEARGoodwillYoY
5.94 MUSD+595.17%
854,153.04USD+578.08%
125,966.71USD-85.25%
854,153.04USD0.00%
854,153.04USD0.00%
854,153.04USD
Access this data via the Eulerpool API

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beigene stock

On Eulerpool you can find the complete historical development of Goodwill Beigene since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Beigene historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Beigene

All Key Metrics — Beigene